This results in reduced ubiquitination of PD-L1 during the cell cycle and lysosomal degradation of PD-L1 during the cell cycle, thereby prolonging its half-life, inducing and stabilizing PD-L1 expression at the cell membrane, and enhancing the ability of PD-L1-expressing tumor cells to suppress T cells and cancer cells for evasion of immune surveillance. The gene discussed is CD274; the disease is neoplasm.